Conference Track

Metastatic Breast Cancer

Source: CCO Independent Conference Coverage of the CCO Independent Conference Coverage of the 2007 San Antonio Breast Cancer Symposium*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Surgical Resection Improves Outcomes in Patients With Stage IV Breast Cancer
Ixabepilone Plus Capecitabine Active in Patients With ER/PgR/HER2-Negative Metastatic Breast Cancer Resistant to Anthracyclines and/or Taxanes
Docetaxel Plus Bevacizumab Active as First-Line Treatment of Metastatic Breast Cancer
Weekly Docetaxel Less Effective Compared With Every-3-Week Dosing in Anthracycline-Resistant Metastatic Breast Cancer
Docetaxel With Gemcitabine or Capecitabine Both Active in Metastatic Breast Cancer
Capecitabine Plus Paclitaxel Active but Not Noninferior to Epirubicin Plus Paclitaxel in First-Line Metastatic Breast Cancer
Administering Trastuzumab After Brain Metastasis Can Prolong OS in Patients With Metastatic Breast Cancer
Continuing Trastuzumab With Capecitabine After Disease Progression Improves Outcomes in Patients With Metastatic Breast Cancer
Weekly Ixabepilone, Carboplatin, and Trastuzumab Active in HER2-Positive Metastatic Breast Cancer
Pertuzumab Plus Trastuzumab Safe and Well Tolerated in Patients With HER2-Positive Metastatic Breast Cancer
Hsp90 Inhibitor Tanespimycin Plus Trastuzumab Active in HER2-Positive Trastuzumab-Refractory Metastatic Breast Cancer

Expert Analysis

Metastatic Breast Cancer

Faculty:

Clifford A. Hudis, MD
Kathy D. Miller, MD
Joyce O’Shaughnessy, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize the use of breast surgery for patients with metastatic breast cancer
Describe chemotherapy combinations used in the treatment of metastatic breast cancer
Cite study results regarding biologic agents used in combination with chemotherapy to treat patients with breast cancer

CME CREDIT INFORMATION

Release Date: 03/10/08

Expiration Date: 03/09/09

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.2 Nursing CE credits

Pharmacists: 1.2 contact hours (0.12 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.